Assess whether a CMC change is a comparability or a new product (63d181)

Situation

After a competitor label that just got a narrower indication, scientific-advice briefing book is what 505(b)(2) development lead can touch in a safety team sitting on a new disproportionate signal. Pharma & Life Sciences will live with A CMC change is a comparability versus A new product on this Pharmacovigilance file.

Decision

505(b)(2) development lead in a safety team sitting on a new disproportionate signal must choose A CMC change is a comparability / A new product using scientific-advice briefing book after a competitor label that just got a narrower indication.

Hypotheses to test

• Scientific-advice briefing book reads as A CMC change is a comparability once a competitor label that just got a narrower indication is lined up to the same Pharma & Life Sciences population.
• Scientific-advice briefing book is closer to A new product after a competitor label that just got a narrower indication; A CMC change is a comparability would over-claim this Pharmacovigilance extract.
• A dual reading is still live in scientific-advice briefing book for 505(b)(2) development lead in a safety team sitting on a new disproportionate signal.
• Scientific-advice briefing book is missing the fact 505(b)(2) development lead needs after a competitor label that just got a narrower indication; stop this Pharma & Life Sciences close.

Analysis required

• Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal.
• Trace CMC, labeling, or pharmacovigilance facts in scientific-advice briefing book after a competitor label that just got a narrower indication.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences Pharmacovigilance file, read scientific-advice briefing book against a competitor label that just got a narrower indication and write the one fact that would move a CMC change is for 505(b)(2) development lead.

Recommendation

Choose A CMC change is a comparability / A new product on this Pharma & Life Sciences / Pharmacovigilance packet (scientific-advice briefing book after a competitor label that just got a narrower indication). The follow-on Pharmacovigilance action is what 505(b)(2) development lead does next: implement the option, assign an owner, and log the missing fact.